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Tandem LC–MSAbstract The chemical pollution of water resources is a major challenge facing the humanity in
this century. Pharmaceuticals and personal care products (PPCPs) are a group of emerging environ-
mental chemical pollutants distinguished by their bioactivity and high solubility. They may also
cause health complications to humans and living organisms. Pharmaceuticals enter the environ-
ment, mainly via wastewater and can eventually reach the surface and ground water. Despite this,
PPCPs received less attention as environmental pollutants than other chemical pollutants (e.g.
heavy metals and pesticides). The purpose of this work was to investigate the presence of some
of the most frequently dispensed drugs for the residents of Almadinah Almunawarah, Saudi Arabia
in the municipal wastewater before and after treatment. For this purpose, wastewater samples were
collected biweekly from the city’s sewage treatment plant for a period of 4 months and analyzed the
targeted drugs using tandem LC–MS. Out of the 19 investigated drugs, 5 pharmaceuticals have been
found in concentrations greater than the limit of detection in both the inﬂuents and efﬂuents of the
sewage treatment plant. As expected, the concentrations of investigated pharmaceuticals in the
wastewater were found to be low. These drugs and their average concentrations (in ng mL1) in
the inﬂuents were: acetaminophen (38.9), metformin (15.2), norﬂuoxetine (7.07), atenolol (2.04),
S720 A. Shraim et al.and cephalexin (1.88). Meanwhile, the efﬂuents contained slightly lower levels (in ng mL1) than
those of inﬂuents: acetaminophen (31.2), metformin (3.19), norﬂuoxetine (7.25), atenolol (0.545),
and cephalexin (1.53). The results of this study supported by many other investigations indicate
the inefﬁciency of current conventional wastewater treatment protocols in eliminating such a group
of active and potentially hazardous pollutants from the wastewater.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Pharmaceuticals and personal care products (PPCPs) are a
group of substances that ‘‘refer, in general, to any product
used by individuals for personal health or cosmetic reasons
or used by agribusiness to enhance growth or health of
livestock’’ (US-EPA). The term PPCPs contain thousands of
different chemical compounds, such as prescription and over-
the-counter therapeutic drugs, veterinary drugs, perfumes,
musks, deodorants, shampoos, hair sprays, hair dyes, body lo-
tions, sun-screens, make-up, nail polish, lipsticks, cre`mes, diag-
nostic agents, and nutraceuticals. Many of these compounds
including pharmaceuticals, the focus of this investigation, are
bioactive, metabolize partially, and biodegrade slowly (Debska
et al., 2004; Hernando et al., 2006; Ku¨mmerer, 2008).
Little attention has been paid to PPCPs in general and
pharmaceuticals in particular as potential environmental pol-
lutants when compared to other chemicals pollutants like hea-
vy metals and pesticides. Interest in pharmaceuticals and their
metabolites and by-products as environmental pollutants has
only initiated in the 1970s, but it was not until recently when
scientists actively began to address the impact of such pollu-
tants on the environment and living organisms (Daughton,
2002; Debska et al., 2004; Fatta et al., 2007; Heberer, 2002;
Hernando et al., 2006; Ku¨mmerer, 2009; Stan and Heberer,
1997; Zuccato et al., 2006).
Current literature shows that pharmaceuticals are continu-
ously released into the environment in extremely large quanti-
ties and on a regular basis through different ways like human
activities (e.g. through excretion and bathing and disposal of
unwanted medications to sewers and trash), wastes from phar-
maceutical industries, residues and wastes from hospitals, use
of illicit and veterinary drugs (especially antibiotics and ste-
roids), and agribusiness (Bartelt-Hunt et al., 2009; Escher
et al., 2011; Larsson et al., 2007; Ternes, 1998).
Due to the fact that pharmaceuticals generally dissolve eas-
ily in aqueous media and do not usually evaporate at normal
temperatures or pressure, they make their way into the soil
and aquatic environments via sewage, treated sewage sludge
(biosolids), and irrigation with reclaimed waters
(Cunningham, 2008; Nikolaou et al., 2007). Current research
ﬁndings clearly demonstrate that current conventional waste-
water treatment technologies do not sufﬁciently remove
pharmaceuticals and/or their metabolites and degradation
by-products from wastewater, and therefore let them reach
surface, marine, ground, and drinking waters (Benotti and
Brownawell, 2007; Debska et al., 2004; Joss et al., 2008).
Although some pharmaceuticals breakdown or degrade
upon consumption or release into the environment, most of
them remain unchanged and eventually become persistent in
the environment. It is known that most of these chemicalsremain bioactive even at extremely low concentrations after
excretion from the body or after disposal to landﬁlls and
waters, have unpredictable biochemical interactions when
mixed together, and may have a tendency to accumulate in
the food chain with negative health impact on aquatic organ-
isms and consumers (Escher et al., 2011; Hernando et al.,
2006; Ku¨mmerer, 2008). As a result, pharmaceuticals and their
metabolites and by-products are of concern for their potential
ecological and environmental impacts.
Recent literature indicates that the ﬂux of pharmaceuticals
from municipal sewage treatment plants (STP) is a consider-
able source of chemical pollution in surface, ground, marine,
and even tap and bottled waters (Chang et al., 2007; Heberer,
2002; Khan and Ongerth, 2002; Kolpin et al., 2002; Rosal
et al., 2010; Ternes, 1998). For instance, an investigation con-
ducted by the U.S. Geological Survey in 1999 to check the
occurrence of PPCPs (e.g. sterols, hormones, pharmaceuticals,
antibiotics) in surface and ground water has conﬁrmed the
presence of at least one PPCP at low levels in more than two
thirds of the samples, with steroids, nonprescription drugs,
and pesticides being the most frequently detected compounds
(Kolpin et al., 2002). Although the concentrations of individ-
ual pharmaceuticals reported in investigated water bodies
worldwide are low and may not cause any harm to the human
health, chronic exposure to a mixture of such compounds may
disturb the balance in the human body and enhance a danger-
ous resistance to antibiotics and consequently pose a threat to
the health of living organisms; a task that many scientists are
currently investigating (Escher et al., 2011; Hernando et al.,
2006; Santos et al., 2007; Schriks et al., 2010). Some of the re-
ported potential effects of PPCPs on living organisms were: de-
layed development in ﬁsh and frogs, delayed metamorphosis in
frogs, increased feminization of ﬁsh populations, and a variety
of reactions including altered behavior and reproduction
(Hernando et al., 2006).
The aim of this work was to investigate the occurrence of
the most frequently prescribed drugs in the inﬂuents and efﬂu-
ents of municipal wastewater of Almadinah Almunawarah.
2. Materials and methods
The list of all pharmaceuticals distributed to the public hospi-
tals and medical clinics in Almadinah Almunawarah area for
the year 2009 was obtained from the Directorate General of
Health Affairs of Almadinah Almunawarah. Some of the most
frequently dispensed drugs have been selected to be investi-
gated in this study, based on their quantities and the possibility
of being detected in wastewater. The targeted drugs and their
amounts are presented in Table 1.
All glass- and plastic-wares used were soaked overnight in
10% nitric acid, rinsed with distilled water, and ﬁnally with
Table 1 List of the most frequently dispensed drugs in the
area of Almadinah Almunawarah along with their quantities














Anticoagulants Warfarin sodium salt 1.1
Antihypertensives Atenolol 269








Diclofenac sodium salt 521
Antiepileptics Carbamazepine 556
Ranitidine 749
GI disorders Hyoscine-N-butyl bromide 51
Antidiabetics Metformin 6,300
Respiratory drugs Chlorpheniramine malate 431
Antidepressant Norﬂuoxetine 2.1
a The most frequently dispensed drug(s) from most of the drug
classes have been selected.
Table 2 Common MS settings.
Ion source polarity Positive and negative ion modes
Capillary voltage 3500 V
Vaporizer temperature 300 C
Nebulizer Pressure 45 psi
Gas Flow 10 L min1
Time Filter True
Time Filter Width Wide
MS1 Resolution Wide
MS2 Resolution Wide
Dwell Time 10 ms
Fragmenter Voltage 135 V
Cell Acceleration Voltage 7 V
Experiment Type: MRM
MS Run Time 13.0 min (acidics and neutrals)
and 18.0 min (basics)
Analysis of some pharmaceuticals in municipal wastewater of Almadinah Almunawarah S721reagent water before use. Glasswares used for the preparation
and storage of drug solutions were rinsed with dimethyldichlo-
rosilane (DMDCS) followed by two toluene rinsings and
several methanol washings before use.
2.1. Chemicals and reagents
The following chemicals and reagents were used: reagent water
(Milli-Q, 18.2 MO cm, Elix10, Millipore, USA), ethylenedi-
aminetetraacetic acid disodium salt dehydrate (Na2ETDA,
Sigma, ACS reagent, 99.0–101.0%), ascorbic acid (Sigma, ul-
tra grade, >99.0%), formic acid (Fischer Scientiﬁc, analytical
reagent grade, 98%), ammonium hydroxide solution (Sigma–
Aldrich, ACS reagent, NH3 content 28–30%), methanol (Sig-
ma–Aldrich, Chromasolv grade, 99.9% min), acetonitrile
(ACN, Fisher Scientiﬁc, HPLC Gradient grade), dimethyldi-
chlorosilane (DMDCS, 5% in toluene), and toluene (GC
grade, 99.5%, Panreac, Barcelona-Spain). The drugs of inter-
est were: acetaminophen (98%), carbamazepine, diclofenac
sodium salt, erythromycin ethyl succinate, norﬂuoxetine
(>97%), ranitidine hydrochloride, scopolamine N-butyl
bromide (hyosine-N-bytyl bromide, >99%), and trimetho-
prim (>98.5%) which were purchased from Sigma–Aldrich,
ibuprofen (>99%), metronidazole (99.9%), sulfamethoxazole
(99.9%), and warfarin sodium salt (99.9%) from Fluka, and
atenolol, captopril, cephalexin, chlorpheniramine maleate,
metformin hydrochloride (99.8%), and simvastatin (98.3%)
were obtained as a gift from Al-Jazeera Pharmaceutical Indus-
tries, Riyadh, Saudi Arabia. Stock solutions of these drugs
(2000 lg mL1) were prepared as follows: approx. 20.0 mg
of each drug was accurately weighed in a glass test tube and
dissolved in 10 mL water or MeOH depending on analyte sol-
ubility. In order to minimize drugs’ degradation, the test tubescontaining the stock solutions were wrapped with aluminum
foil and stored refrigerated at 4 C. Working solutions of single
analytes as well as mixtures of analytes (10.0 ng mL1 each)
were prepared in methanol as required from the stock solu-
tions and stored in a similar way as for the stock solutions.
Three types of HPLC mobile phases were prepared: formic
acid (A1, 0.3% (v/v) in water); ammonium hydroxide (A2,
20 mM in water); and acetonitrile: methanol (B, 2:1).
2.2. Samples collection and pre-treatment
Wastewater samples were collected from the only STP in
Almadinah Almunawarah. The current total capacity of this
plant is 300,000 m3 day1. In addition to domestic sewage,
the plant sometimes receives partially-treated industrial and
medical wastewater. The plant undertakes tertiary treatment.
Most of the treated wastewater is discharged into the nearby
Al-Khlail wadi (valley) and used mainly for irrigation, and
about 15% of this water is transported in trucks and used
for watering of green areas and trees in public parks and streets
of Almadinah Almunawarah.
Wastewater samples have been collected biweekly for a per-
iod of 4 months both from the inlet of the plant after initial
screening (inﬂuents) and from the outlet after chlorination (ter-
tiary treated, efﬂuents). Composite samples were collected for
24 h using a portable water sampler (WS750 dual bottle sam-
pler from Global Water, CA, USA) at a rate of 100 mL h1.
The procedure described by Batt et al. (2008) for the anal-
ysis of pharmaceuticals in waste and surface water was
adopted for this work with modiﬁcations. Batt et al. procedure
was developed and applied for the analysis of pharmaceuticals
in wastewater and surface water samples obtained from New
Mexico and East Fork River in Cincinnati, Ohio, respectively.
The pH of the samples was measured upon arrival to the lab-
oratory and found to be close to neutral values (pH 7.2–7.6)
and therefore the samples were used without any pH adjust-
ment. The samples were then ﬁltered using a vacuum ﬁlter fun-
nel (porosity 25–50 lm, Aldrich). To each 500 mL of ﬁltered
samples, a 2 mL solution containing Na2ETDA (5.00 g L
1,
used as a metal chelating agent) and ascorbic acid (25.0 mg L1,
used to remove any chlorine residues that may be present in
the samples) was added before extraction.
Table 3 Speciﬁc MS settings (all analyzed in + ESI mode, except diclofenac sodium salt and ibuprofen for which –ESI more was
used).
Name RTa Formula Wt Precursor Ion Product Ion 1 Product Ion 2 CEb DTc LODd
Acetaminophen 0.94 151.17 152.2 110.0 93.0 11 10 0.90
Atenolol 0.80 266.34 267.6 145.2 74.2 23 10 0.22
Captopril 0.63 217.29 218.5 70.0 115.5 23 10 6.1
Carbamazepine 5.36 236.27 237.5 194.4 179.3 15 10 0.25
Cephalexin 0.92 365.41 348.9 158.0 174.9 7 10 0.32
Chlorpheniramine maleate 3.85 390.86 275.6 230.4 – 11 10 0.35
Diclofenac sodium salt 3.69 318.13 295.8 250.0 – 4 100 1.33
Erythromycin Ethylsuccinate 1.25 862.1 862.5 387.1 – 15 10 2.1
Ibuprofen 4.36 207.23 207.1 161.0 118.9 2 100 0.91
Hyoscine-N-butylbromide 2.20 440.38 360.1 194.2 – 23 10 1.0
Metformin 0.70 129.16 130.1 60.1 71.1 19 10 3.0
Metronidazole 2.80 171.15 172.2 128.1 82.0 11 10 0.32
Norﬂuoxetine 3.67 295.3 295.8 278.6 137.8 15 10 1.1
Ranitidine hydrochloride 0.80 350.86 315.8 130.0 127.1 11 10 0.11
Simvastatin 11.94 418.57 419.7 225.4 244.5 5 100 1.0
Sulfamethoxazole 0.69 253.28 254.6 156.0 189.2 11 10 0.21
Trimethoprim 0.90 290.32 291.7 122.9 – 19 10 0.23
Warfarin sodium salt 12.306 308.31 309.8 252.4 164.0 11 10 1.8
a RT is the retention time (min) of pure standards using A1:B mobile phase except for diclofenac sodium salt and ibuprofen A2:B mobile
phase was used.
b CE is collision energy (eV).
c DT is Dwell Time (ms).
d LOD is the limit of detection in ng mL1.
S722 A. Shraim et al.Analytes in the samples were extracted at the same day of
collection using Oasis MCX cartridges (mixed mode, 150 mg
from Waters, Milford, MA, USA). The material inside these
cartridges is made of hydrophobic-lipophilic balanced copoly-
mer that can retain acidic, basic, and neutral analytes. A drug
behaves as an acid, base, or neutral in solution based on the
functional group(s) it processes and on the pH of the solution.
In this context, ‘‘acidic and neutral’’ analytes described in this
work are those pharmaceuticals that are eluted off the SPE
Oasis MCX cartridge with ACN, whereas basic analytes are
those that are eluted by ACN in 5% ammonium hydroxide.
The reason for dividing the analytes into 2 groups (‘‘acidic
and neutrals’’ and basics) was to enhance the sensitivity of
the MS detector and to avoid any complexity during analysis.
Before extraction, each SPE cartridge was conditioned with
ACN (6 mL) followed by reagent water (6 mL). Samples pre-
pared as described above were passed through reconditioned
cartridges at a rate of 3–5 mL min1 with the aid of a vacuum
pump. Each cartridge was then slowly rinsed with a 2 mL solu-
tion of formic acid (2%) and allowed to dry under vacuum.
Acidic and neutral analytes in each sample were ﬁrst eluted
with ACN (2 · 4 mL) into a small glass tube using a vacuum
manifold (20 positions from Waters, Milford, MA, USA). Ba-
sic analytes retained on the cartridge material were then eluted
by ACN solution (2 · 4 mL) containing ammonium hydroxide
(5%) into a separate glass tube. Each eluate was then concen-
trated to dryness with the help of a TurboVap LV Concentra-
tion Evaporator Workstation (Caliper Life Sciences, Runcorn,
UK) at 40 C under a gentle stream of N2. The contents of the
ﬁrst tube were reconstituted with ACN in water (0.50 mL,
20 + 80), whereas the eluate in the other tube was reconsti-
tuted with MeOH in water (0.50 mL, 20 + 80). The ﬁrst frac-
tion is termed from now on as ‘‘acidics and neutrals,’’ whereasthe second one as ‘‘basics.’’ Reconstituted samples were trans-
ferred to glass vials and analyzed by LC–MS. This procedure
has been ﬁrst tried using solutions of mixed standards as
described in the section 2.3.2 below.
2.3. Samples analysis
2.3.1. UV analyses
In order to identify absorption wavelengths suitable for mon-
itoring the analytes during the method development, a UV
scan for each analyte was performed using a UV–Vis spec-
trometer (Jasco, Ubest V-50) as follows: 10.0 mg L1 solution
of each drug was prepared in the A1-B mobile phase (1:1 ratio)
and the spectra were taken in the range of 200–400 nm using
quartz cells. Same procedure was repeated but using the other
mobile phase (A2–B, ratio1:1). Blank solutions were also ana-
lyzed using both A1–B and A2–B mobile phases in 1:1 ratios.
2.3.2. HPLC-DAD analyses
Method development was undertaken using an HPLC system
(1290 series, Agilent Technologies, USA) equipped with a diode
array detector (DAD). For the separation of the analytes, a
SunFire column (C18, 2.1 · 150 mm, 3.5 lm, Waters, Milford,
MA, USA) preceded by a guard column (SunFire, C18,
2.1 · 10 mm, 3.5 lm, Waters, Milford, MA, USA) was used
at a temperature of 40 C. A gradient elution program was
set as follows with a mobile phase ﬂow rate of 0.5 mL min1.
For acidic and neutral analytes, the A2–B mobile phase was
used with an initial mobile phase of 10% solvent B and held
for 0.5 min. The ratio of the mobile phase B was then linearly
increased to 40% over 1 min and held for 2.5 min, then to
90% over 0.5 min and held for 0.5 min. The initial mobile phase
composition was restored in 0.5 min and the column was equil-
Figure 1 Extracted MRM chromatogram (1a), mass spectrum (1b), and product ion spectrum (1c) for acetaminophen.
Analysis of some pharmaceuticals in municipal wastewater of Almadinah Almunawarah S723ibrated for an additional 7.5 min (total run time is 13.0 min).
The DAD wavelength was set at 210 nm (this wavelength was
found to be suitable for all analytes as discussed in Section
3.1). For the basic analytes, the A1–B mobile phase was used
with an initial composition of 10% B and was held for
0.5 min. The ratio of the mobile phase B was then linearly in-
creased to 30% over 0.5 min, then to 35% over 2 min and held
for 7 min, and ﬁnally to 90% over 1 min and held for 0.5 min.
The initial mobile phase composition was restored in 0.5 min
and the column was equilibrated for 6.0 min (total run time is
18.0 min). The following wavelengths have been found to be
suitable for detecting basic analytes 225, 230, 240, and
270 nm (refer to Section 3.1 for details).
To determine the elution pattern of the analytes, a 20 lL of
each drug solution (1000.0 lg mL1) was individually injected
to the HPLC column using the two HPLC protocols described
above. Following this, the two groups of analytes eluted from
the SPE as acidics and neutrals (group 1) or as basics (group
2) have been identiﬁed as follows: a mixed standard solution
containing all analytes (10 mL of 1000.0 lg mL1) has been ex-
tracted, eluted, evaporated, and reconstituted using the sameprocedure employed for the samples (see Section 2.2). Blank
solution has been treated in a similar way. Consequently, a
20 lL of each of the reconstituted solutions of the two groups
of analyteswas injected to theHPLCcolumn.Acidic andneutral
analytes were analyzed using the A2–B mobile phase, whereas
basic analytes were analyzed using the A1–B mobile phase.2.3.3. LC–MS/MS analyses
Due to the superior sensitivity of MS detection when com-
pared to UV as well as the complexity of the samples matrix,
MS was used as a detector.
As a mean to identify the molecular ion masses and the
retention times of the analytes, a 10 lL solution of each ana-
lyte (1000.0 lg mL1) was injected to the LC–MS system (Agi-
lent 1290 UHPLC and 6460 MS/MS series with Jet Steam ESI
source) using a mobile phase ﬂow rate of 0.5 mL min1. Then,
a product ion scan employing the multiple monitoring reaction
mode (MRM) was performed to collect data for suitable prod-
uct ions. The two most intense MRM transitions were then se-
lected for all analytes except for chlorpheniramine maleate,
Figure 2 Extracted MRM chromatogram (2a), mass spectrum (2b), and product ion spectrum (2c) for atenolol.
S724 A. Shraim et al.diclofenac sodium salt, erythromycin ethylsuccinate, hyoscine-
n-butylbromide, and trimethoprim, for which only one prod-
uct ion was present. The MRM transitions were optimized
using different collision energies. The utilized common MS set-
tings are listed in Table 2, whereas the speciﬁc settings were
shown next to each analyte in Table 3. After establishing the
MRM, the two groups of analytes (extracted by the cartridges
as described at the end of Section 2.3.3) have also been injected
to the LC–MS system to conﬁrm the results obtained by
HPLC-DAD. Finally, calibration standard solutions and trea-
ted samples solutions were injected to the LC–MS system. For
quantiﬁcation of the analytes, a 4-point calibration curve for
each analyte was constructed at concentrations of 0.000,
100.00, 500.00, and 1000.0 lg mL1. The R2-value for the
curves was better than 0.998. For LC–MS analysis, same
chromatographic conditions (i.e. column, mobile phases, and
gradient elution programs) used for HPLC-DAD analyses
were employed. For detection of the analytes both the reten-
tion time and product ion ratios were used. Analytes were pos-
itively identiﬁed if both product ions are present in abundancemore than the LOD and the ratio of the ions is within 30% of
the anticipated ratio.
The limit of detection (LOD) for each analyte was deter-
mined using 5–7 replicate injections of a reagent blank and
was calculated as the average concentration measured for the
blank multiplied by 3 times its standard deviation.3. Results and discussion
3.1. UV analysis
According to the UV spectra of all analytes (not shown here)
an optimal wavelength of 210–215 nm can be used for all ana-
lytes when using the A2–B (1:1) mobile phase (210 nm was
used). On the other hand, the use of the A1–B (1:1) mobile
phase resulted in a different spectral pattern and a different
optimal wavelength was obtained for most of the analytes.
Additionally the following compounds showed no absorption





Figure 3 Extracted MRM chromatogram (3a), mass spectrum (3b), and product ion spectrum (3c) for cephalexin.
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consequence multiple wavelengths have been used to monitor
the analytes: 225, 230, 240, and 270 nm; each of them has been
used to monitor a sub group of the analytes.
3.2. HPLC-DAD analysis
Experiments conducted as described in Section 2.2 above
showed that the analytes eluted as basics were: atenolol, rani-
tidine, simvastatin, and trimethoprim. In contrast, erythromy-
cin ethyl succinate showed no HPLC-DAD signal, but
conﬁrmed by LC–MS to elute in the basics group. The rest
of the analytes was eluted in the acidics and neutrals fraction.
3.3. LC–MS/MS Analysis
Several solid phase extraction cartridges were used in the liter-
ature for the extraction of pharmaceuticals from wastewater
including Oasis HLB, Oasis MCX, Oasis WCX, Strata-X,Supelco C8, Supelco C18, Varian Focus, and Merck
LiChrolut-EN. The Oasis MCX, which was employed in this
work, has been shown to provide high overall recoveries. (Batt
et al., 2008; Lacey et al., 2008).
Extracted MRM chromatogram, mass spectrum, and prod-
uct ion spectrum for each analyte that has been detected in the
wastewater in concentrations greater than the LOD are shown
in Figs. 1–5. Out of the 19 targeted drugs, 5 pharmaceuticals
have been found both in raw (inﬂuents) and treated (efﬂuents)
wastewater samples. The concentrations of these pharmaceuti-
cals are shown in Tables 4 and 5. Although most pharmaceu-
ticals have high solubility in water and hence remain soluble in
the aqueous phase, some drugs have lower solubility and re-
main insoluble as the solid material in wastewater. Since the
samples were ﬁltered before extraction, the reported concen-
trations in this work represent only the water-soluble fraction
of the analytes.
The detected drugs have been found in most of the samples as
shown in Tables 4 and 5. As expected, the concentrations of indi-
Figure 4 Extracted MRM chromatogram (4a), mass spectrum (4b), and product ion spectrum (4c) for metformin.
S726 A. Shraim et al.vidual pharmaceuticals in the wastewater inﬂuents were found to
be low with an average concentration of 2.04–38.9 ng mL1.
The highest detected concentration was for acetaminophen
(99.6 ng mL1), followed by metformin (31.2 ng mL1), nor-
ﬂuoxetine (10.4 ng mL1), atenolol (4.03 ng mL1), and cepha-
lexin (3.23 ng mL1). Interestingly, the amounts of these
pharmaceuticals in the treated wastewater (efﬂuents) did not dif-
fermuch from those found in the rawwastewater (inﬂuents), with
a concentration range of 0.545–31.2 ng mL1. The highest con-
centration detected was for acetaminophen (90.5 ng mL1), fol-
lowed by norﬂuoxetine (11.7 ng mL1), cephalexin (2.83 ng mL1),
metformin (4.51 ng mL1), and atenolol (2.01 ng mL1).
The ﬁndings of this study is consistent with those of many
reports in the literature, where low concentrations of pharma-
ceuticals have been found in municipal wastewater
(Bartelt-Hunt et al., 2009; Batt et al., 2008; Gracia-Lor et al.,
2010; Mie`ge et al., 2009; Radjenovic et al., 2009; Rosal et al.,
2010). For example, Rosal et al. reported the occurrence ofaround 70 pharmaceuticals and PPCPs in inﬂuents of
municipal wastewater with some compounds in the ng mL1
concentration range (e.g. paraxanthine, caffeine, and acetami-
nophen), whereas the rest were in the ng L1 range (Rosal
et al., 2010). In another study by Gracia-Lor et al., 13 out of
20 investigated drugs were detected in the inﬂuents of urban
wastewater samples with salicylic acid having the highest
concentration (276.7 ng mL1) (Gracia-Lor et al., 2010).
On the other hand, efﬂuents of urban wastewater and
receiving waters were reported also to contain many pharma-
ceuticals at low concentrations. (Bartelt-Hunt et al., 2009;
Gracia-Lor et al., 2010; Joss et al., 2008; Lacey et al., 2008;
Santos et al., 2007; Soliman et al., 2007; Spongberg and Witter,
2008; Ternes, 1998; Zhou et al., 2009) Clearly, this indicates
that most of the current wastewater treatment practices are
inefﬁcient in completely removing such contaminants. For in-
stance, 5 pharmaceuticals (i.e. propranolol, sulfamethoxazole,





Figure 5 Extracted MRM chromatogram (5a), mass spectrum (5b), and product ion spectrum (5c) for norﬂuoxetine.
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England with carbamazepine having the highest levels
(2.336 ng mL1). The reported removal efﬁciencies for these
compounds from the wastewater were in the range of 43–
92%.(Zhou et al., 2009) In another study, 5 out of 6 drugs (dic-
lofenac, ibuprofen, ketoprofen, naproxen, carbamazepine, and
caffeine) have been detected in both inﬂuent and efﬂuent sam-
ples from 4 STPs in Seville–Spain in the ng mL1 concentra-
tion range. The reported removal rates for these drugs were
between 6% and 98%. (Santos et al., 2007) Similarly, 5 out
of 10 pharmaceuticals detected in the inﬂuents of 3 STPs in
Duplin-Ireland have been found in the wastewater efﬂuents
with concentrations of <1 ng mL1 for most samples (Lacey
et al., 2008).
The removal efﬁciency of pharmaceuticals from wastewater
is actually dependent on several factors including the climatic
conditions, the type of wastewater treatment and its opera-
tional conditions (e.g. temperature, redox conditions, solids
and hydraulic retention time) as well as the age of the activatedsludge used in the plant, but the main factor is reported to be
the physico-chemical nature of most pharmaceuticals, which is
the acidity and high solubility in water with very low solid–
liquid partition. These factors, especially the last one lead to
a very poor sorption of these compounds onto sludge and
hence leaving them soluble in the aqueous phase (Gracia-Lor
et al., 2012; Verlicchi et al., 2012).
It is also worth noting here that some of the pharmaceuticals
that were detected in the wastewater were also found in the
sludge of the wastewater treatment plans. This is due to the
low solubility of such drugs and therefore they remain insoluble
and appear in the sludge (Gao et al., 2012; Jelic et al., 2011).
When considering a single pharmaceutical at low concen-
trations such as those reported in this investigation and other
work, it may be assumed that not many health risks can be
associated with long term exposure to such a drug. But the
health risks associated with exposure to a large number of
pharmaceuticals, their metabolites, and transformation prod-
ucts, even at low concentrations, cannot be ignored.
Table 4 Concentrations of pharmaceuticals (ng mL1) in raw wastewater samples.
Sample IDa Metformin Atenolol Cephalexin Acetaminophen Norﬂuoxetine
1R 9.01 2.04 2.52 99.6 10.4
2R 16.5 2.02 2.04 58.7 9.11
3R 17.0 4.03 <MDL 40.5 8.43
4R 4.02 1.04 2.01 3.61 10.4
5R 13.0 2.99 3.23 29.0 7.03
6R 25.1 2.02 1.48 36.7 7.64
7R 31.2 1.97 2.09 5.51 2.48
8R 5.93 <MDL 1.37 37.7 <MDL
Range 4.02–31.2 <MDL - 4.03 <MDL - 3.23 3.61–99.6 <MDL - 10.4
Median 14.8 2.02 2.03 37.2 8.04
Average 15.2 2.04 1.88 38.9 7.07
a R means raw wastewater (inﬂuents).
Table 5 Concentrations of pharmaceuticals (ng mL1) in treated wastewater samples.
Sample ID a Metformin Atenolol Cephalexin Acetaminophen Norﬂuoxetine
1T <LOD 2.01 2.21 16.1 11.7
2T <LOD <LOD 1.68 <LOD 9.81
3T <LOD 1.03 <LOD <LOD 9.72
4T <LOD <LOD 1.27 48.8 8.17
5T <LOD <LOD 2.83 <LOD 9.57
6T <LOD <LOD <LOD 90.5 <LOD
7T <LOD <LOD 1.74 44.8 6.83
8T 4.51 <LOD 1.88 46.7 <LOD
Range <LOD - 4.51 <LOD - 2.01 <LOD - 2.83 <LOD – 90.5 <LOD – 11.7
Median <LOD <LOD 1.71 30.5 8.87
Average 3.19 0.545 1.53 31.2 7.25
a T means treated wastewater (efﬂuents).
S728 A. Shraim et al.4. Conclusions
Out of the 19 pharmaceuticals investigated in this study, 5
drugs have been found both in the inﬂuents and efﬂuents of
the STP. The concentrations of these drugs in both types were
in the lower ng mL1 (inﬂuents range 2.04–38.9, max. 99.6;
efﬂuents range 0.545–31.2, max. 90.5) with efﬂuents having
slightly lower concentrations than the inﬂuents in most cases.
The results of this investigation, supported by a similar
work in the literature, indicate that many drugs (including
their metabolites and transformation products) are not efﬁ-
ciently eliminated during the wastewater treatment processes
(sometimes tertiary treatment, as in this study). This may sug-
gest that conventional wastewater treatment technologies are
inefﬁcient in completely removing such compounds and as a
consequence leaving the way open for such bioactive com-
pounds to enter the aquatic environment and eventually pol-
lute the drinking water supplies and pose health risks to
humans and other living organisms.
Although, the levels of detected pharmaceuticals in the trea-
ted water are quite low, the health risks associated with long
term exposure to a large number of pharmaceuticals have to
be kept in mind.
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